End-points in clinical trials for liver cancer and their value in evidence based clinical decision making: an unresolved Gordian knot.

[1]  M. Sherman.  Assessing Toxicity in Drug Trials in Liver Disease , 2021, Seminars in Liver Disease.

[2]  J. Bruix,et al.  Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. , 2020, European journal of radiology.

[3]  M. Londoño,et al.  Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors , 2020, Cancers.

[4]  D. DeMets,et al.  When Can Intermediate Outcomes Be Used as Surrogate Outcomes? , 2020, JAMA.

[5]  Michael Koller,et al.  International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. , 2020, The Lancet. Oncology.

[6]  N. Chalasani,et al.  Consensus guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease , 2019, Alimentary pharmacology & therapeutics.

[7]  J. Bruix,et al.  Insights into the success and failure of systemic therapy for hepatocellular carcinoma , 2019, Nature Reviews Gastroenterology & Hepatology.

[8]  V. Prasad,et al.  Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials. , 2019, JAMA internal medicine.

[9]  C. Porta,et al.  Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. , 2018, The Lancet. Oncology.

[10]  J. Bruix,et al.  Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. , 2017, Journal of hepatology.

[11]  Lesley Seymour,et al.  RECIST — learning from the past to build the future , 2017, Nature Reviews Clinical Oncology.

[12]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[13]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[14]  J. Bruix,et al.  Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST , 2014, Seminars in Liver Disease.

[15]  J. Bruix,et al.  Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second‐line trial design , 2013, Hepatology.

[16]  L. Schwartz,et al.  When progressive disease does not mean treatment failure: reconsidering the criteria for progression. , 2012, Journal of the National Cancer Institute.

[17]  D. Sargent,et al.  Biomarkers and surrogate end points—the challenge of statistical validation , 2010, Nature Reviews Clinical Oncology.

[18]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[19]  Jordi Rimola,et al.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma , 2009, Cancer.

[20]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[21]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[22]  J. Hanley,et al.  The effect of measuring error on the results of therapeutic trials in advanced cancer , 1976, Cancer.

[23]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[24]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.